View Financial HealthMemphasys 배당 및 자사주 매입배당 기준 점검 0/6Memphasys 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-23.3%자사주 매입 수익률총 주주 수익률-23.3%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesBoard Change • May 20High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairperson of the Board Lindley Edwards is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Board Change • May 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairperson of the Board Lindley Edwards is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공시 • Feb 16Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.8 million.Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 160,000,000 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0003 Transaction Features: Subsequent Direct Listing공시 • Feb 06Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 0.8 million.Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 0.8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 160,000,000 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0003 Transaction Features: Subsequent Direct ListingBoard Change • Dec 31High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairperson of the Board Lindley Edwards is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공시 • Dec 30Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 1.120549 million.Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 1.120549 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 180,460,810 Price\Range: AUD 0.003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 193,055,540 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Rights Offering공시 • Oct 21Memphasys Limited, Annual General Meeting, Nov 20, 2025Memphasys Limited, Annual General Meeting, Nov 20, 2025. Location: at level 32, 200 george street, sydney nsw 2000 Australia공시 • Oct 20Memphasys Limited Announces Board Changes, Effective 20 October 2025Memphasys Limited announced that Dr. David Ali will step down as Executive Director effective 20 October 2025. Dr. Ali will continue in his role as Chief Executive Officer (CEO), with a dedicated focus on the operational and executional aspects of the business as the Company advances the commercialisation of the FelixTM System. This change reflects Memphasys' strategic pivot toward commercialisation, marking a transition from product development to global market rollout. With multiple distribution agreements progressing and CE marking expected in early 2026, operational discipline and execution have become central to the Company's success. Concentrating Dr. Ali's focus solely on operations will ensure optimal delivery against these commercial milestones. As part of this evolution, Mr. Marjan Mikel has assumed the role of Chair of Commercialisation, overseeing strategy, partnerships, and market expansion initiatives. This reinforces the Company's commitment to disciplined growth, partnership-driven scaling, and commercial excellence. The company also announced the appointment of Mr. Mathew Watkins as an Independent Non- Executive Director, effective 20 October 2025. Mr. Watkins is a Chartered Accountant and member of the Governance Institute of Australia with extensive ASX experience across biotechnology, bioscience, resources, and information technology sectors. He specialises in ASX statutory reporting, compliance, corporate governance, and board and secretarial support. Mr. Watkins serves as Company Secretary for several ASX-listed entities and is currently the SEA Regional Practice Lead & Australia Market Lead at Vistra (Australia) Pty Ltd.공시 • Oct 04Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 1.120549 million.Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 1.120549 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 373,516,350 Price\Range: AUD 0.003 Transaction Features: Rights Offering공시 • Sep 23Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.8925 million.Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.8925 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 297,500,000 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Transaction Features: Subsequent Direct ListingNew Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$3.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.1m free cash flow). Share price has been highly volatile over the past 3 months (32% average weekly change). Earnings have declined by 32% per year over the past 5 years. Shareholders have been substantially diluted in the past year (37% increase in shares outstanding). Revenue is less than US$1m (AU$532k revenue, or US$348k). Market cap is less than US$10m (AU$7.93m market cap, or US$5.19m).Reported Earnings • Aug 31Full year 2025 earnings releasedFull year 2025 results: Net loss: AU$4.94m (loss widened 11% from FY 2024).Board Change • Aug 18Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Paul Wright was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Jun 20Memphasys Limited Appoints Marjan Mikel as Non-Executive DirectorMemphasys Limited announced the appointment of Mr. Marjan Mikel as a Non-Executive Director of the Company, effective immediately. Mr. Mikel brings a strong and diverse track record in business development, commercial leadership, capital markets, and strategic partnership execution across the Medtech, diagnostics, healthcare services, and life sciences sectors. He has held senior executive and board positions in both listed and private companies, with extensive experience in the commercialization of disruptive technologies and scaling ventures in regulated markets. He is currently the CEO and Managing Director of Vitasora Health Limited, an ASX-listed remote patient monitoring company operating in the U.S. healthcare system. Under his leadership, the company has pioneered the commercialization of a novel respiratory monitoring device and successfully transitioned into a full-service RPM provider. Mr. Mikel led capital raises, secured major U.S. ACO and payer contracts, and executed the cross-border acquisition of U.S.-based Orb Health, expanding the company's footprint and capabilities in the U.S. market. Previously, Mr. Mikel founded Healthy Sleep Solutions, building it into Australia's largest sleep health provider before securing ResMed as a strategic investor and leading a successful trade sale to global multinational Air Liquide. He also held senior commercial roles with IMS Health, Merck Sharp & Dohme, Pharmacia, and Searle, with responsibilities across Australia, Asia-Pacific, and Europe. Importantly, Mr. Mikel is familiar with Memphasys and its strategic vision, having previously served as a Non-Executive Director of the Company from June 2018 to March 2020, including as Chair of both the Audit & Risk Committee and the Nomination & Remuneration Committee. Mr. Mikel holds a Master of Commerce from the University of New South Wales, a Graduate Diploma in Education, and a Bachelor of Science (Hons) from the University of Sydney and has completed executive studies at the Australian Graduate School of Management. He is also a Member of the Australian Institute of Company Directors (MAICD).공시 • Apr 17Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2755 million.Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2755 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 212,583,334 Price\Range: AUD 0.006 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Apr 10Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 1.275 million.Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 1.275 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 212,500,000 Price\Range: AUD 0.006 Transaction Features: Subsequent Direct ListingNew Risk • Dec 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 57% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 33% per year over the past 5 years. Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Revenue is less than US$1m (AU$1.1m revenue, or US$678k). Market cap is less than US$10m (AU$10.6m market cap, or US$6.61m).공시 • Nov 06+ 1 more updateMemphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.857 million.Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.857 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 142,833,292 Price\Range: AUD 0.006 Security Features: Attached Options공시 • Sep 25Memphasys Limited, Annual General Meeting, Oct 25, 2024Memphasys Limited, Annual General Meeting, Oct 25, 2024. Location: level 1, 34-36 richmond road, homebush west nsw 2140, AustraliaNew Risk • Sep 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Earnings have declined by 33% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m (AU$1.3m revenue, or US$854k). Market cap is less than US$10m (AU$13.0m market cap, or US$8.72m).Reported Earnings • Aug 31Full year 2024 earnings releasedFull year 2024 results: Net loss: AU$4.44m (loss widened 31% from FY 2023).공시 • Aug 30Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.5 million.Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 62,500,000 Price\Range: AUD 0.008 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Jul 29Memphasys Limited announced that it has received AUD 0.5 million in fundingMemphasys Limited entered into a subscription agreement with Andrew Goodall for issuance of 62,500,000 common shares at a price of AUD 0.008 per share for gross proceeds of AUD 500,000 on July 29, 2024.New Risk • Feb 28New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$3.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.8m free cash flow). Earnings have declined by 31% per year over the past 5 years. Revenue is less than US$1m (AU$656k revenue, or US$429k). Market cap is less than US$10m (AU$12.3m market cap, or US$8.05m). Minor Risk Shareholders have been diluted in the past year (43% increase in shares outstanding).공시 • Jan 10Memphasys Limited, Annual General Meeting, Feb 14, 2024Memphasys Limited, Annual General Meeting, Feb 14, 2024, at 10:00 AUS Eastern Standard Time. Location: 30 Richmond Road, Homebush West New South Wales Australia Agenda: To consider APPROVAL OF ISSUE OF SHARES TO PETERS INVESTMENTS ON CONVERSION OF CONVERTIBLE NOTES; to consider APPROVAL TO ISSUE OPTIONS FREE ATTACHING TO PLACEMENT SHARES; to consider APPROVAL TO ISSUE SHARES AND OPTIONS TO RELATED PARTY UNDER THE PLACEMENT ON CONVERSION OF SHORT-TERM LOANS MR ANDREW GOODALL; and to discuss other matters.New Risk • Dec 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m (AU$624k revenue, or US$410k). Market cap is less than US$10m (AU$14.7m market cap, or US$9.64m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding).공시 • Dec 04Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 4.232268 million.Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 4.232268 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 210,000,000 Price\Range: AUD 0.01 Discount Per Security: AUD 0.0006 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 213,226,752 Price\Range: AUD 0.01 Discount Per Security: AUD 0.0006 Security Features: Attached Options Transaction Features: Rights Offering; Subsequent Direct ListingReported Earnings • Sep 01Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.003 loss in FY 2022)Full year 2023 results: AU$0.002 loss per share. Net loss: AU$3.40m (loss widened 63% from FY 2022).공시 • Aug 31Memphasys Limited, Annual General Meeting, Nov 22, 2023Memphasys Limited, Annual General Meeting, Nov 22, 2023, at 11:00 E. Australia Standard Time. Location: 30 Richmond Road, 2140 Homebush West New South Wales AustraliaNew Risk • Jun 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.4m (US$9.66m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.8m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 22% per year over the past 5 years. Revenue is less than US$1m (AU$72k revenue, or US$48k). Market cap is less than US$10m (AU$14.4m market cap, or US$9.66m). Minor Risk Shareholders have been diluted in the past year (21% increase in shares outstanding).공시 • Feb 07Memphasys Limited Announces the First Publications of Study Findings by Key Opinion Leaders (KOLs) of the Felix SystemMemphasys Limited announced the first publications of study findings by key opinion leaders (KOLs) of the Felix System - a patented, automated device for quickly and gently separating high quality sperm from a semen sample for use in human IVF procedures. A published article entitled "Spermatozoa isolation with Felix outperforms conventional density gradient centrifugation preparation in selecting cells with low DNA damage" featured in Andrology, the official journal of the American society of Andrology and European Academy of Andrology, on 11th January 2023. The research was conducted by renowned French genetics reproduction and development lab (GReD), supported by the University Clermont Auvergne (UCA), and led by Professor Joel Drevet, an international leader in mammalian andrology ("the KOL"). The KOL studied 29 human semen samples which were analysed fresh and after DGC or Felix System preparation and were monitored by sample volume, sperm count, total motility, progressive motility, sperm DNA fragmentation using the Sperm Chromatin Structure Assay ("SCSA") and sperm DNA oxidation. Results of the study highlighted spermatozoa preparation with Felix System "significantly improved spermatozoa fractions with higher progressive motility, lower sperm DNA fragmentation, and lower sperm DNA oxidation compared with raw semen and DGC-prepared spermatozoa". The article noted that the study data supported spermatozoa preparation by the Felix system "as it allows selection of spermatozoa with the highest progressive motility as well as the lowest nuclear/DNA damage." The article concluded that "These improved sperm parameters, along with the fact that the Felix separation process is very fast and highly standardized, should be of great interest to the assisted reproduction technologies industry." In addition, another article entitled "A comparison between the Felix electrophoretic system of sperm isolation and conventional density gradient centrifugation: a multicentre analysis", has been published in Journal of Assisted Reproduction and Genetics, an official journal of the American Society for Reproductive Medicine. Supported by Memphasys, the research was conducted and collaborated across five KOLs namely: Monash IVF, Australia; Andrology Center, India; The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, USA; GeneraLife IVF, Sweden; Reproductive and Genetic Hospital, People's Republic of China. The KOLs compared the quality of the sperm populations isolated by the Felix System and DGC in terms of processing time, sperm concentration, motility, vitality, and DNA integrity as assessed by 3 methods: SCSA, Halo, and TUNEL. Across all KOLs, 112 comparisons were performed with findings highlighting the Felix system "is a positive technical development capable of isolating suspensions of highly motile spermatozoa in a fraction of the time taken by conventional procedures such as DGC." Four of the five centres reported a significant improvement in DNA integrity relative to DGC (one reported no statistical difference but both methods selected sperm with low DNA damage). The Felix system isolates sperm in a standardised 6-minute preparation time whereas clinical DGC protocols vary between sites but generally took around 40 minutes to complete.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Paul Wright was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Aug 18Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Paul Wright was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jul 22Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Paul Wright was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • May 05Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Paul Wright was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 MEM 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: MEM 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Memphasys 배당 수익률 vs 시장MEM의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (MEM)n/a시장 하위 25% (AU)2.8%시장 상위 25% (AU)6.8%업계 평균 (Life Sciences)2.3%분석가 예측 (MEM) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 MEM 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 MEM 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 MEM 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: MEM 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YAU 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 21:11종가2026/05/22 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Memphasys Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Board Change • May 20High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairperson of the Board Lindley Edwards is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Board Change • May 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairperson of the Board Lindley Edwards is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공시 • Feb 16Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.8 million.Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 160,000,000 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0003 Transaction Features: Subsequent Direct Listing
공시 • Feb 06Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 0.8 million.Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 0.8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 160,000,000 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0003 Transaction Features: Subsequent Direct Listing
Board Change • Dec 31High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairperson of the Board Lindley Edwards is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공시 • Dec 30Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 1.120549 million.Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 1.120549 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 180,460,810 Price\Range: AUD 0.003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 193,055,540 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Rights Offering
공시 • Oct 21Memphasys Limited, Annual General Meeting, Nov 20, 2025Memphasys Limited, Annual General Meeting, Nov 20, 2025. Location: at level 32, 200 george street, sydney nsw 2000 Australia
공시 • Oct 20Memphasys Limited Announces Board Changes, Effective 20 October 2025Memphasys Limited announced that Dr. David Ali will step down as Executive Director effective 20 October 2025. Dr. Ali will continue in his role as Chief Executive Officer (CEO), with a dedicated focus on the operational and executional aspects of the business as the Company advances the commercialisation of the FelixTM System. This change reflects Memphasys' strategic pivot toward commercialisation, marking a transition from product development to global market rollout. With multiple distribution agreements progressing and CE marking expected in early 2026, operational discipline and execution have become central to the Company's success. Concentrating Dr. Ali's focus solely on operations will ensure optimal delivery against these commercial milestones. As part of this evolution, Mr. Marjan Mikel has assumed the role of Chair of Commercialisation, overseeing strategy, partnerships, and market expansion initiatives. This reinforces the Company's commitment to disciplined growth, partnership-driven scaling, and commercial excellence. The company also announced the appointment of Mr. Mathew Watkins as an Independent Non- Executive Director, effective 20 October 2025. Mr. Watkins is a Chartered Accountant and member of the Governance Institute of Australia with extensive ASX experience across biotechnology, bioscience, resources, and information technology sectors. He specialises in ASX statutory reporting, compliance, corporate governance, and board and secretarial support. Mr. Watkins serves as Company Secretary for several ASX-listed entities and is currently the SEA Regional Practice Lead & Australia Market Lead at Vistra (Australia) Pty Ltd.
공시 • Oct 04Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 1.120549 million.Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 1.120549 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 373,516,350 Price\Range: AUD 0.003 Transaction Features: Rights Offering
공시 • Sep 23Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.8925 million.Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.8925 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 297,500,000 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Transaction Features: Subsequent Direct Listing
New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$3.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.1m free cash flow). Share price has been highly volatile over the past 3 months (32% average weekly change). Earnings have declined by 32% per year over the past 5 years. Shareholders have been substantially diluted in the past year (37% increase in shares outstanding). Revenue is less than US$1m (AU$532k revenue, or US$348k). Market cap is less than US$10m (AU$7.93m market cap, or US$5.19m).
Reported Earnings • Aug 31Full year 2025 earnings releasedFull year 2025 results: Net loss: AU$4.94m (loss widened 11% from FY 2024).
Board Change • Aug 18Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Paul Wright was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Jun 20Memphasys Limited Appoints Marjan Mikel as Non-Executive DirectorMemphasys Limited announced the appointment of Mr. Marjan Mikel as a Non-Executive Director of the Company, effective immediately. Mr. Mikel brings a strong and diverse track record in business development, commercial leadership, capital markets, and strategic partnership execution across the Medtech, diagnostics, healthcare services, and life sciences sectors. He has held senior executive and board positions in both listed and private companies, with extensive experience in the commercialization of disruptive technologies and scaling ventures in regulated markets. He is currently the CEO and Managing Director of Vitasora Health Limited, an ASX-listed remote patient monitoring company operating in the U.S. healthcare system. Under his leadership, the company has pioneered the commercialization of a novel respiratory monitoring device and successfully transitioned into a full-service RPM provider. Mr. Mikel led capital raises, secured major U.S. ACO and payer contracts, and executed the cross-border acquisition of U.S.-based Orb Health, expanding the company's footprint and capabilities in the U.S. market. Previously, Mr. Mikel founded Healthy Sleep Solutions, building it into Australia's largest sleep health provider before securing ResMed as a strategic investor and leading a successful trade sale to global multinational Air Liquide. He also held senior commercial roles with IMS Health, Merck Sharp & Dohme, Pharmacia, and Searle, with responsibilities across Australia, Asia-Pacific, and Europe. Importantly, Mr. Mikel is familiar with Memphasys and its strategic vision, having previously served as a Non-Executive Director of the Company from June 2018 to March 2020, including as Chair of both the Audit & Risk Committee and the Nomination & Remuneration Committee. Mr. Mikel holds a Master of Commerce from the University of New South Wales, a Graduate Diploma in Education, and a Bachelor of Science (Hons) from the University of Sydney and has completed executive studies at the Australian Graduate School of Management. He is also a Member of the Australian Institute of Company Directors (MAICD).
공시 • Apr 17Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2755 million.Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 1.2755 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 212,583,334 Price\Range: AUD 0.006 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Apr 10Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 1.275 million.Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 1.275 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 212,500,000 Price\Range: AUD 0.006 Transaction Features: Subsequent Direct Listing
New Risk • Dec 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 57% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 33% per year over the past 5 years. Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Revenue is less than US$1m (AU$1.1m revenue, or US$678k). Market cap is less than US$10m (AU$10.6m market cap, or US$6.61m).
공시 • Nov 06+ 1 more updateMemphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.857 million.Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.857 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 142,833,292 Price\Range: AUD 0.006 Security Features: Attached Options
공시 • Sep 25Memphasys Limited, Annual General Meeting, Oct 25, 2024Memphasys Limited, Annual General Meeting, Oct 25, 2024. Location: level 1, 34-36 richmond road, homebush west nsw 2140, Australia
New Risk • Sep 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Earnings have declined by 33% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Revenue is less than US$1m (AU$1.3m revenue, or US$854k). Market cap is less than US$10m (AU$13.0m market cap, or US$8.72m).
Reported Earnings • Aug 31Full year 2024 earnings releasedFull year 2024 results: Net loss: AU$4.44m (loss widened 31% from FY 2023).
공시 • Aug 30Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.5 million.Memphasys Limited has completed a Follow-on Equity Offering in the amount of AUD 0.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 62,500,000 Price\Range: AUD 0.008 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Jul 29Memphasys Limited announced that it has received AUD 0.5 million in fundingMemphasys Limited entered into a subscription agreement with Andrew Goodall for issuance of 62,500,000 common shares at a price of AUD 0.008 per share for gross proceeds of AUD 500,000 on July 29, 2024.
New Risk • Feb 28New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$3.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.8m free cash flow). Earnings have declined by 31% per year over the past 5 years. Revenue is less than US$1m (AU$656k revenue, or US$429k). Market cap is less than US$10m (AU$12.3m market cap, or US$8.05m). Minor Risk Shareholders have been diluted in the past year (43% increase in shares outstanding).
공시 • Jan 10Memphasys Limited, Annual General Meeting, Feb 14, 2024Memphasys Limited, Annual General Meeting, Feb 14, 2024, at 10:00 AUS Eastern Standard Time. Location: 30 Richmond Road, Homebush West New South Wales Australia Agenda: To consider APPROVAL OF ISSUE OF SHARES TO PETERS INVESTMENTS ON CONVERSION OF CONVERTIBLE NOTES; to consider APPROVAL TO ISSUE OPTIONS FREE ATTACHING TO PLACEMENT SHARES; to consider APPROVAL TO ISSUE SHARES AND OPTIONS TO RELATED PARTY UNDER THE PLACEMENT ON CONVERSION OF SHORT-TERM LOANS MR ANDREW GOODALL; and to discuss other matters.
New Risk • Dec 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m (AU$624k revenue, or US$410k). Market cap is less than US$10m (AU$14.7m market cap, or US$9.64m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding).
공시 • Dec 04Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 4.232268 million.Memphasys Limited has filed a Follow-on Equity Offering in the amount of AUD 4.232268 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 210,000,000 Price\Range: AUD 0.01 Discount Per Security: AUD 0.0006 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 213,226,752 Price\Range: AUD 0.01 Discount Per Security: AUD 0.0006 Security Features: Attached Options Transaction Features: Rights Offering; Subsequent Direct Listing
Reported Earnings • Sep 01Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.003 loss in FY 2022)Full year 2023 results: AU$0.002 loss per share. Net loss: AU$3.40m (loss widened 63% from FY 2022).
공시 • Aug 31Memphasys Limited, Annual General Meeting, Nov 22, 2023Memphasys Limited, Annual General Meeting, Nov 22, 2023, at 11:00 E. Australia Standard Time. Location: 30 Richmond Road, 2140 Homebush West New South Wales Australia
New Risk • Jun 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.4m (US$9.66m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.8m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 22% per year over the past 5 years. Revenue is less than US$1m (AU$72k revenue, or US$48k). Market cap is less than US$10m (AU$14.4m market cap, or US$9.66m). Minor Risk Shareholders have been diluted in the past year (21% increase in shares outstanding).
공시 • Feb 07Memphasys Limited Announces the First Publications of Study Findings by Key Opinion Leaders (KOLs) of the Felix SystemMemphasys Limited announced the first publications of study findings by key opinion leaders (KOLs) of the Felix System - a patented, automated device for quickly and gently separating high quality sperm from a semen sample for use in human IVF procedures. A published article entitled "Spermatozoa isolation with Felix outperforms conventional density gradient centrifugation preparation in selecting cells with low DNA damage" featured in Andrology, the official journal of the American society of Andrology and European Academy of Andrology, on 11th January 2023. The research was conducted by renowned French genetics reproduction and development lab (GReD), supported by the University Clermont Auvergne (UCA), and led by Professor Joel Drevet, an international leader in mammalian andrology ("the KOL"). The KOL studied 29 human semen samples which were analysed fresh and after DGC or Felix System preparation and were monitored by sample volume, sperm count, total motility, progressive motility, sperm DNA fragmentation using the Sperm Chromatin Structure Assay ("SCSA") and sperm DNA oxidation. Results of the study highlighted spermatozoa preparation with Felix System "significantly improved spermatozoa fractions with higher progressive motility, lower sperm DNA fragmentation, and lower sperm DNA oxidation compared with raw semen and DGC-prepared spermatozoa". The article noted that the study data supported spermatozoa preparation by the Felix system "as it allows selection of spermatozoa with the highest progressive motility as well as the lowest nuclear/DNA damage." The article concluded that "These improved sperm parameters, along with the fact that the Felix separation process is very fast and highly standardized, should be of great interest to the assisted reproduction technologies industry." In addition, another article entitled "A comparison between the Felix electrophoretic system of sperm isolation and conventional density gradient centrifugation: a multicentre analysis", has been published in Journal of Assisted Reproduction and Genetics, an official journal of the American Society for Reproductive Medicine. Supported by Memphasys, the research was conducted and collaborated across five KOLs namely: Monash IVF, Australia; Andrology Center, India; The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, USA; GeneraLife IVF, Sweden; Reproductive and Genetic Hospital, People's Republic of China. The KOLs compared the quality of the sperm populations isolated by the Felix System and DGC in terms of processing time, sperm concentration, motility, vitality, and DNA integrity as assessed by 3 methods: SCSA, Halo, and TUNEL. Across all KOLs, 112 comparisons were performed with findings highlighting the Felix system "is a positive technical development capable of isolating suspensions of highly motile spermatozoa in a fraction of the time taken by conventional procedures such as DGC." Four of the five centres reported a significant improvement in DNA integrity relative to DGC (one reported no statistical difference but both methods selected sperm with low DNA damage). The Felix system isolates sperm in a standardised 6-minute preparation time whereas clinical DGC protocols vary between sites but generally took around 40 minutes to complete.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Paul Wright was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Aug 18Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Paul Wright was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jul 22Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Paul Wright was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • May 05Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Paul Wright was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.